Analysts Offer Insights on Healthcare Companies: MannKind (MNKD), Repligen (RGEN) and Travere Therapeutics (TVTX)
MannKind Corporation to Participate in the Lytham Partners Fall 2022 Investor Conference
7 Penny Stocks That Actually Have a Buy Rating
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Penny stocks are always a risky proposition. However, investors can still find cheap shares with buy ratings right now. The post 7 Penny Stocks That Actually Have a Buy Rating appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live The Best $1 Investment You Can Make Today Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air” It doesn’t matter if you have $500 or $5 million. Do this now.
MannKind (NASDAQ:MNKD) Stock Passes Above 200 Day Moving Average of $3.72
MannKind Co. (NASDAQ:MNKD – Get Rating)'s stock price passed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $3.72 and traded as high as $3.72. M
After Losing 20% in the Past Year, MannKind Corporation (NASDAQ:MNKD) Institutional Owners Must Be Relieved by the Recent Gain
If you want to know who really controls MannKind Corporation (NASDAQ:MNKD), then you'll have to look at the makeup of its share registry. We can see that institutions own the lion's share in the comp
SVB Securities Keeps Their Buy Rating on MannKind (MNKD)
Analysts Conflicted on These Healthcare Names: Zymeworks (ZYME), Cooper Co (COO) and MannKind (MNKD)
Cantor Fitzgerald Biotech/pharma Analysts Hold Analyst/industry Conference Call
Biopharma & Biotech Analyst Chen, Medical Devices Analyst Folkes, Biotech Analyst Brayer and Biopharma Analyst Kim, along with Dr. Berger, Cardiologist at Fairview Health Services, discuss new PAH
MannKind Shares Fall After Completing Initial Stage Lung Disease Study
MannKind Corporation (NASDAQ:MNKD) has successfully completed a Phase 1 study of clofazimine inhalation suspension (MNKD 101), an inhalation treatment option for nontuberculous mycobacterial (NTM) lun
Today's Pre-Market Stock Movers: DWAC, BBBY, ILMN, DBX and More
Illumina confirms it intends to appeal European Commission's decision in GRAIL deal.